J Rheum Dis.  2017 Jun;24(3):143-148. 10.4078/jrd.2017.24.3.143.

Platelet Distribution Width and Mean Platelet Volume Are Not Correlated with the Disease Activity Indices of Ankylosing Spondylitis

• Byun S
• Jung SM
• Song JJ
• Park YB
• Lee SW

• KMID: 2385341
• DOI: http://doi.org/10.4078/jrd.2017.24.3.143

Abstract

OBJECTIVE
We investigated the association of platelet distribution width (PDW) and mean platelet volume (MPV) with disease activity indices of ankylosing spondylitis (AS) in patients whose laboratory results or medical conditions would not affect PDW and MPV levels.
METHODS
We analysed demographic and laboratory data of 88 patients with AS. On the same day as the laboratory tests were done, we assessed AS disease activity using the Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Patients Global Score and Ankylosing Spondylitis Disease Activity Score (ASDAS), including erythrocyte sedimentation rate (ESR) (ASDAS-ESR) and C-reactive protein (CRP) (ASDAS-CRP). The association was analyzed by linear regression.
RESULTS
The median age of 88 patients was 38.0 years and the median length of observation was 5.5 years. The median platelet count was 266,500.0/µL, the median PDW was 10.7 fL and the median MPV 9.6 fL. The median ESR was 19.0 mm/hr and CRP was 2.5 mg/L. Among acute reactants, only CRP was negatively correlated with MPV, but not PDW (r=−0.218, p<0.041). However, both PDW and MPV were not significantly correlated with any disease activity index of AS. On multivariate linear regression analysis, only the length of observation was significantly correlated with MPV (β=0.224, p<0.044).
CONCLUSION
PDW and MPV were not potent surrogate markers to reflect AS activity, with potential confounding strictly controlled, to affect MPV and PDW levels.

Keyword

Mean platelet volume; Platelt count; Ankylosing spondylitis

MeSH Terms

Baths
Biomarkers
Blood Platelets*
Blood Sedimentation
C-Reactive Protein
Humans
Linear Models
Mean Platelet Volume*
Platelet Count
Spondylitis, Ankylosing*
Biomarkers
C-Reactive Protein

Figure

• 

  Figure 1. Selection of the study population. HbA1c: haemoglobin A1c, INR: international normalized ratio.

Reference

1. Sieper J. New treatment targets for axial spondyloarthritis. Rheumatology (Oxford). 2016; 55(suppl 2):ii38–ii42.

2. Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol. 1999; 26:971–4.

3. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis. 2011; 70:1375–81.

4. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21:2286–91.

5. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994; 21:2281–5.

6. Jones SD, Steiner A, Garrett SL, Calin A. The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol. 1996; 35:66–71.

7. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994; 21:1694–8.

8. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-en-dorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68:1811–8.

9. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012; 44:805–16.

10. Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med. 2014; 52:1107–17.

11. Esen B, Atay AE, Gunoz N, Gokmen ES, Sari H, Cakir I, et al. The relation of mean platelet volume with microalbuminuria and glomerular filtration rate in obese individuals without other metabolic risk factors: the role of platelets on renal functions. Clin Nephrol. 2015; 83:322–9.

12. Kurt M, Onal IK, Sayilir AY, Beyazit Y, Oztas E, Kekilli M, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology. 2012; 59:1580–2.

13. Ju HY, Kim JK, Hur SM, Woo SA, Park KA, Park MY, et al. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease? Platelets. 2015; 26:143–7.

14. Karabacak M, Dogan A, Turkdogan AK, Kapci M, Duman A, Akpinar O. Mean platelet volume is increased in patients with hypertensive crises. Platelets. 2014; 25:423–6.

15. Varol E, Ozaydin M. Mean platelet volume measurement in patients with hypercholesterolemia: a methodological issue. Angiology. 2013; 64:626.

16. Wang X, Xu XL, Li XM, Zhao R, Yang X, Cong HL. Diagnostic value of mean platelet volume combined with troponin i for acute coronary syndrome. Am J Med Sci. 2016; 352:159–65.

17. Tecer D, Sezgin M, Kanık A, İncel NA, Çimen ÖB, Biçer A, et al. Can mean platelet volume and red blood cell distribution width show disease activity in rheumatoid arthritis? Biomark Med. 2016; 10:967–74.

18. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75:291–4.

19. Şahin A, Yetişgin A, Şahin M, Durmaz Y, Cengiz AK. Can mean platelet volume be a surrogate marker of inflammation in rheumatic diseases? West Indian Med J. 2015; 65:165–9.

20. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Platelets. 2010; 21:126–31.

21. Sezgin M, Tecer D, Kanık A, Kekik FS, Yeşildal E, Akaslan E, et al. Serum RDW and MPV in ankylosing spondylitis: Can they show the disease activity? Clin Hemorheol Microcirc. 2017; 65:1–10.

22. Resorlu H, Resorlu M, Gokmen F, Akbal A, Adam G, Komurcu E, et al. Association between mean platelet volume and bone mineral density in patients with ankylosing spondylitis and diagnostic value of diffusion-weighted magnetic resonance imaging. J Phys Ther Sci. 2015; 27:1137–40.

23. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27:361–8.

24. Cho SY, Jeon YL, Kim W, Kim WS, Lee HJ, Lee WI, et al. Mean platelet volume and mean platelet volume/platelet count ratio in infective endocarditis. Platelets. 2014; 25:559–61.

25. Bessman JD, Williams LJ, Gilmer PR Jr. Platelet size in health and hematologic disease. Am J Clin Pathol. 1982; 78:150–3.

26. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115:3339–47.

27. Lee SW, Park HJ, Kim BK, Han KH, Lee SK, Kim SU, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther. 2012; 14:R232.

28. De Luca G, Secco GG, Iorio S, Verdoia M, Bellomo G, Marino P. Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study. Blood Coagul Fibrinolysis. 2012; 23:756–9.